FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1543835592> ?p ?o ?g. }

• W1543835592 endingPage "1244" @default.
• W1543835592 startingPage "1237" @default.
• W1543835592 abstract "What's known on the subject? and What does the study add? Lymph node (LN) status is one of the most important prognostic variables in patients undergoing radical prostatectomy, but not all patients with node-positive PCa are at the same risk of recurrence and cancer-specific death. In this study we evaluated the role of pathological variables in stratifying the risk of cancer death in patients with prostate cancer. Patients with 1–3 positive LNs and Gleason score (GS) ≤7 experienced better CSS and OS than those with >3 metastatic LNs and/or GS >7. This evidence could allow urologists to better predict oncological outcomes of patients and select more appropriate therapeutic management. Objectives To evaluate the outcomes in patients with node-positive prostate cancer (PCa) after radical prostatectomy (RP) and pelvic lymph node dissection (PLND) according to the number of positive lymph nodes (LNs). To identify different risk groups among patients with node-positive PCa. Patients and Methods We evaluated 98 consecutive patients with pN1M0 PCa who underwent RP between November 1995 and May 2011. Kaplan–Meier and Cox proportional univariable and multivariable regression models were used to analyse the survival rates. Patients were divided into two groups according to number of positive LNs using the most informative positive LN theshold for predicting survival, then into three different risk groups according to number of positive LNs and pathological Gleason score (GS). Results Mean (range) follow-up was 68.4 (10–192) months. Patients with 1–3 positive LNs (n = 75; 76.5%) had significantly better cancer-specific survival (CSS) and overall survival (OS) compared with those with >3 positive nodes (n = 23; 23.4%; P < 0.01). Patients with 1–3 positive LNs and pathological GS ≤7 (Group 1) had significantly better CSS than those with >3 positive LNs or GS 8–10 (Group 2 [P = 0.015]). Group 2 patients, moreover, had significantly better CSS (P = 0.019) and OS (P = 0.021) than those with >3 positive LNs and GS 8–10 (Group 3). Conclusions Patients with 1–3 positive LNs have higher CSS and OS rates than those with >3 metastatic LNs. Taking into account the pathological GS, as well as the number of positive nodes, three risk group categories with considerable differences in terms of survival can be found. Patients with LN-positive PCa should be stratified into different groups according to these two measures, to obtain a better prediction of oncological outcomes." @default.
• W1543835592 created "2016-06-24" @default.
• W1543835592 creator A5005989484 @default.
• W1543835592 creator A5009887316 @default.
• W1543835592 creator A5011075020 @default.
• W1543835592 creator A5011935671 @default.
• W1543835592 creator A5021881282 @default.
• W1543835592 creator A5025316738 @default.
• W1543835592 creator A5029088271 @default.
• W1543835592 creator A5063552641 @default.
• W1543835592 creator A5080019020 @default.
• W1543835592 creator A5080774729 @default.
• W1543835592 creator A5087080299 @default.
• W1543835592 date "2013-01-17" @default.
• W1543835592 modified "2023-10-17" @default.
• W1543835592 title "Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: identification of risk categories according to number of positive nodes and Gleason score" @default.
• W1543835592 cites W1497903288 @default.
• W1543835592 cites W1901153912 @default.
• W1543835592 cites W1974753376 @default.
• W1543835592 cites W1975388728 @default.
• W1543835592 cites W1977875850 @default.
• W1543835592 cites W1996080642 @default.
• W1543835592 cites W2004625759 @default.
• W1543835592 cites W2013930636 @default.
• W1543835592 cites W2033829751 @default.
• W1543835592 cites W2044137132 @default.
• W1543835592 cites W2055568623 @default.
• W1543835592 cites W2071811128 @default.
• W1543835592 cites W2075007329 @default.
• W1543835592 cites W2075338951 @default.
• W1543835592 cites W2075835897 @default.
• W1543835592 cites W2077219580 @default.
• W1543835592 cites W2080487345 @default.
• W1543835592 cites W2093795110 @default.
• W1543835592 cites W2099335474 @default.
• W1543835592 cites W2123230901 @default.
• W1543835592 cites W2142391938 @default.
• W1543835592 cites W2149758685 @default.
• W1543835592 cites W2158334167 @default.
• W1543835592 cites W2160679358 @default.
• W1543835592 cites W2170401524 @default.
• W1543835592 cites W2462273439 @default.
• W1543835592 cites W2765085843 @default.
• W1543835592 cites W4239180165 @default.
• W1543835592 cites W4322701587 @default.
• W1543835592 doi "https://doi.org/10.1111/j.1464-410x.2012.11602.x" @default.
• W1543835592 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23331345" @default.
• W1543835592 hasPublicationYear "2013" @default.
• W1543835592 type Work @default.
• W1543835592 sameAs 1543835592 @default.
• W1543835592 citedByCount "27" @default.
• W1543835592 countsByYear W15438355922013 @default.
• W1543835592 countsByYear W15438355922014 @default.
• W1543835592 countsByYear W15438355922015 @default.
• W1543835592 countsByYear W15438355922016 @default.
• W1543835592 countsByYear W15438355922017 @default.
• W1543835592 countsByYear W15438355922018 @default.
• W1543835592 countsByYear W15438355922019 @default.
• W1543835592 countsByYear W15438355922020 @default.
• W1543835592 countsByYear W15438355922021 @default.
• W1543835592 countsByYear W15438355922022 @default.
• W1543835592 countsByYear W15438355922023 @default.
• W1543835592 crossrefType "journal-article" @default.
• W1543835592 hasAuthorship W1543835592A5005989484 @default.
• W1543835592 hasAuthorship W1543835592A5009887316 @default.
• W1543835592 hasAuthorship W1543835592A5011075020 @default.
• W1543835592 hasAuthorship W1543835592A5011935671 @default.
• W1543835592 hasAuthorship W1543835592A5021881282 @default.
• W1543835592 hasAuthorship W1543835592A5025316738 @default.
• W1543835592 hasAuthorship W1543835592A5029088271 @default.
• W1543835592 hasAuthorship W1543835592A5063552641 @default.
• W1543835592 hasAuthorship W1543835592A5080019020 @default.
• W1543835592 hasAuthorship W1543835592A5080774729 @default.
• W1543835592 hasAuthorship W1543835592A5087080299 @default.
• W1543835592 hasConcept C121608353 @default.
• W1543835592 hasConcept C126322002 @default.
• W1543835592 hasConcept C126894567 @default.
• W1543835592 hasConcept C141071460 @default.
• W1543835592 hasConcept C143998085 @default.
• W1543835592 hasConcept C146357865 @default.
• W1543835592 hasConcept C151730666 @default.
• W1543835592 hasConcept C207886595 @default.
• W1543835592 hasConcept C2775862295 @default.
• W1543835592 hasConcept C2777008409 @default.
• W1543835592 hasConcept C2779466945 @default.
• W1543835592 hasConcept C2780192828 @default.
• W1543835592 hasConcept C2780849966 @default.
• W1543835592 hasConcept C29456083 @default.
• W1543835592 hasConcept C50382708 @default.
• W1543835592 hasConcept C71924100 @default.
• W1543835592 hasConcept C86803240 @default.
• W1543835592 hasConceptScore W1543835592C121608353 @default.
• W1543835592 hasConceptScore W1543835592C126322002 @default.
• W1543835592 hasConceptScore W1543835592C126894567 @default.
• W1543835592 hasConceptScore W1543835592C141071460 @default.
• W1543835592 hasConceptScore W1543835592C143998085 @default.
• W1543835592 hasConceptScore W1543835592C146357865 @default.
• W1543835592 hasConceptScore W1543835592C151730666 @default.

• next